Q3 FY2026 · ended Sep 30, 2026 · Revenue $63.45M, +74.6% YoY · Filed Nov 5, 2026
Cronos Group Inc. (CRON) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $63.5 million and net income of $13.8 million. Free cash flow was $24.4 million. As of Sep 30, 2026 it held $741.2 million in cash and investments and $1.2 million in total debt.
Revenue
$63.45M
+74.6% vs year-ago quarter
Net income
$13.80M
-46.8% vs year-ago quarter
Operating cash flow
$34.34M
+158.0% vs year-ago quarter
Free cash flow
$24.39M
+176.3% vs year-ago quarter
EPS
$0.04
-42.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
366.47M
-4.3% vs year-ago quarter
Net cash
$739.96M
Q3 FY2026
Operating margin
3.4%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- CRON (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Stayner, Ontario, Canada
- SEC filer status
- Accelerated filer
- SEC CIK
- 1656472
- Former names
- PharmaCan Capital Corp. (until May 27, 2016)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $63.5M | $53.0M | $45.2M | $44.5M | $36.3M |
| Operating income | $9.0M | $7.4M | -$1.8M | -$7.5M | -$503,000 |
| Net income | $13.8M | $32.1M | $13.8M | -$1.8M | $26.0M |
| Diluted EPS | $0.04 | $0.09 | $0.04 | -$0.00 | $0.07 |
| Operating cash flow | $34.3M | $24.0M | $10.9M | $11.8M | $13.3M |
| Free cash flow | $24.4M | $22.3M | $9.0M | $9.7M | $8.8M |
| Total assets | $1.2B | $1.2B | $1.2B | $1.2B | $1.2B |
| Total liabilities | $73.4M | $62.4M | $48.3M | $54.2M | $46.4M |
| Stockholders' equity | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Cash and investments | $741.2M | $797.0M | $821.9M | $831.8M | $824.2M |
| Total debt | $1.2M | $1.3M | $1.3M | $1.5M | $1.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 11, 2026 | Sep 8, 2026 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Aug 7, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 501 Cronos Group Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.